Harmony Biosciences Holdings, Inc.
Bear Case (25th pct.)
-1.8% vs price
Base Case (Median)
16.3% vs price
Bull Case (75th pct.)
73.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $28.85 | -24.4% | High (40%) |
| PE Comparable | $68.54 | 79.7% | Medium (25%) |
| Growth Trajectory DCF | $64.10 | 68.1% | Medium (20%) |
| Graham Number | $32.39 | -15.1% | Medium (40%) |
| EV/EBITDA | $44.36 | 16.3% | Medium (20%) |
| EV/FCF | $123.46 | 223.7% | Medium (20%) |
| Earnings Power Value | $42.49 | 11.4% | Medium (50%) |
Based on 7 out of 8 methods, HRMY appears fairly valued at the current price of $38.14. The base case fair value of $44.36 implies 16.3% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.